Get the Stockscreener App
25.01
0.81%
0.20
After Hours:
24.42
-0.59
-2.36%
Ultragenyx Pharmaceutical Inc stock is traded at $25.01, with a volume of 1.48M.
It is up +0.81% in the last 24 hours and up +11.40% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
See More
Previous Close:
$24.81
Open:
$24.96
24h Volume:
1.48M
Relative Volume:
0.72
Market Cap:
$2.46B
Revenue:
$672.72M
Net Income/Loss:
$-575.44M
P/E Ratio:
-4.2854
EPS:
-5.8361
Net Cash Flow:
$-487.00M
1W Performance:
+1.96%
1M Performance:
+11.40%
6M Performance:
-21.52%
1Y Performance:
-35.66%
1-Day Range:
$24.45
$25.32
1-Week Range:
$23.71
$25.32
52-Week Range:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
25.01 | 2.44B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS - MarketBeat
Earnings call transcript: Ultragenyx Q1 2026 results miss forecasts By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript - Benzinga
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance Singapore
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
ULTRAGENYX PHARMACEUTICAL ($RARE) Releases Q1 2026 Earnings - Quiver Quantitative
Ultragenyx: Q1 Earnings Snapshot - KING5.com
Two FDA decisions by September put Ultragenyx gene therapies in focus - Stock Titan
Gene therapy reviews and Q1 2026 results at Ultragenyx (RARE) - Stock Titan
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update - The Manila Times
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 Shares - MarketBeat
Ultragenyx CFO Howard Horn sells $116,606 in company stock - Investing.com
Ultragenyx (RARE) CFO trims stake with 4,683-share open-market sale - Stock Titan
MSN Money - MSN
Mucopolysaccharidoses Market to Reach USD 4,389.85 Million - openPR.com
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Momentum And Ongoing Losses - Sahm
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street Zen - MarketBeat
Affiliate sales notice for RARE (NASDAQ: RARE) lists recent Howard Horn transactions - Stock Titan
Pictet Asset Management Holding SA Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx falls as guidance trails consensus amid job cuts - MSN
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Rare's DTX301 meets first key goal in Phase III OTC deficiency study - MSN
Vanguard Portfolio Management discloses 5.5% stake in Ultragenyx (RARE) - Stock Titan
Ultragenyx earnings: What to watch as pipeline faces key test By Investing.com - Investing.com India
Ultragenyx earnings: What to watch as pipeline faces key test - Investing.com
Barclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat
RARE Maintained by Barclays -- Price Target Lowered to $43 - GuruFocus
Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial - Yahoo Finance
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update - marketscreener.com
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Rare rises as FDA accepts resubmitted BLA for Sanfilippo syndrome - MSN
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
FDA decision on UX111 gene therapy for Sanfilippo expected in September - Sanfilippo Syndrome News
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA - MSN
RARE stock slumps on multiple Wall Street price target slashes, clinical pipeline uncertainty - MSN
Teacher Retirement System of Texas Purchases 327,502 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Above 50-Day Moving AverageHere's Why - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ultragenyx (RARE) SVP Huizenga awarded RSUs and option grant - Stock Titan
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(RARE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Is Ultragenyx Pharmaceutical (RARE) Now Attractive After Recent 8.1% Weekly Share Price Jump - Sahm
Ultragenyx (RARE) CEO gets new RSUs, options and shifts 400K shares - Stock Titan
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):